Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

23-08-2022 | ASO Research Letter

Transgender and Non-binary Persons in Contemporary Oncology Randomized Clinical Trials

Authors: Enrique O. Martinez, BS, Micah Rubin, BA, Tessa Miller, MPH, Chandler S. Cortina, MD, MS, FSSO, FACS

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

An increasing number of individuals in the United States identify as transgender or non-binary (TGNB), defined as a person who’s gender is different from their sex assigned at birth or an individual who does not identify within the male/female gender dichotomy.1 The stigmatization of TGNB individuals has led to significant healthcare disparities in oncologic care.2, 3 There is a paucity of data surrounding oncologic risks, screening, and cancer care for persons on gender-affirming hormone therapy (GAHT), after gender-affirming procedures, or how the physiologic and psychosocial changes from gender-affirming therapies may alter response to cancer treatment.2, 3 Current research aims to elucidate the potential long-term effects of gender-affirming care, especially in the biological development of hormonally sensitive malignancies such as breast, prostate, and gynecological cancers.4, 5 …
Literature
1.
2.
3.
4.
5.
6.
Metadata
Title
Transgender and Non-binary Persons in Contemporary Oncology Randomized Clinical Trials
Authors
Enrique O. Martinez, BS
Micah Rubin, BA
Tessa Miller, MPH
Chandler S. Cortina, MD, MS, FSSO, FACS
Publication date
23-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12418-y

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

ASO Visual Abstract

ASO Visual Abstract: Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting—A Retrospective Analysis

ASO Visual Abstract

ASO Visual Abstract: Hepatectomy is Beneficial for Select Patients with Multiple Hepatocellular Carcinomas

Breast Oncology

Recognizing Disparities in Breast Cancer Patient-Reported Outcome Measures

ASO Author Reflections

ASO Author Reflections: Insufficient Preoperative Smoking Cessation May Deteriorate Postoperative Prognosis for Esophageal Cancer

Sarcoma

Lymph Node Metastases in Gastrointestinal Stromal Tumors: an Uncommon Event

ASO Visual Abstract

ASO Visual Abstract: Short-Term Outcomes of Epidural Analgesia in Minimally Invasive Esophagectomy for Esophageal Cancer: Nationwide Inpatient Data Study in Japan